Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as carboplatin and docetaxel, work in different
ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Giving carboplatin together with docetaxel after surgery may kill any tumor cells
that remain after surgery.
PURPOSE: This phase II trial is studying how well giving carboplatin together with docetaxel
works in treating patients with stage I, stage II, or stage III non-small cell lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
UNC Lineberger Comprehensive Cancer Center
Collaborators:
Aventis Pharmaceuticals National Cancer Institute (NCI)